Phosphodiesterase inhibitors in the management of primary pulmonary hypertension.
Jue
Vicki I
VI
Department of Clinical Pharmacy, University of California San Francisco, San Francisco, CA 94143, USA. vjue3013@itsa.ucsf.edu
D002121:Calcium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D016232:Endothelins / Q000037:antagonists & inhibitors; D011464:Epoprostenol / Q000031:analogs & derivatives; D006801:Humans; D006976:Hypertension, Pulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D018579:Patient Selection; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use; D011687:Purines; D000068677:Sildenafil Citrate; D013450:Sulfones; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000494:pharmacology / Q000627:therapeutic use
D002121:Calcium Channel Blockers; D016232:Endothelins; D010726:Phosphodiesterase Inhibitors; D010879:Piperazines; D011687:Purines; D013450:Sulfones; D014665:Vasodilator Agents; D000068677:Sildenafil Citrate; D011464:Epoprostenol